Colorectal Cancer
Mainz Biomed Taps DCN Dx to Aid European Study of Enhanced ColoAlert Assay
The diagnostics and research services firm will help Mainz recruit research partners for a study assessing new biomarker additions to its CRC early detection test.
Amgen Turning to Combination Strategies After Limited Lumakras Efficacy in KRAS-Mutated Colon Cancer
Data published in Lancet Oncology showed that six out of 62 KRAS G12C-mutated colorectal cancer patients, or 9.7 percent, responded to Lumakras.
Mainz Biomed, Ganzimmun Diagnostics Partner to Commercialize Colorectal Cancer Test
Mainz's ColoAlert test combines fecal immunochemistry with an analysis of cell DNA from stool to detect colorectal cancer at the earliest stages.
Freenome Raises $300M in Series D Financing
The company will use the funding to support commercialization of its blood-based colorectal cancer detection test and to fuel expansion to other tumor types.
Redx Pharma, Caris Life Sciences Partner for Colorectal Cancer Phase II Drug Study Recruitment
The pharma firm is using Caris’ comprehensive molecular profiling to help advance its investigational Porcupine inhibitor, RXC004, in the US.